Načítá se...
Systemic Treatment Options in Hepatocellular Carcinoma
BACKGROUND: Patients with advanced hepatocellular carcinoma (HCC) typically have poor survival outcomes. Until recently, sorafenib was the only systemic therapy option available and no agents were approved after sorafenib failure. However, rapid changes are beginning to emerge in the treatment lands...
Uloženo v:
| Vydáno v: | Liver Cancer |
|---|---|
| Hlavní autoři: | , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
S. Karger AG
2019
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6883446/ https://ncbi.nlm.nih.gov/pubmed/31799201 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1159/000499765 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|